Search clinical trials for: ranibizumab 1.0mg

Total 1991 results

Suzhou Alphamab Co., Ltd.
Novotech (Australia) Pty Limited

Completed

A Study to Evaluate Effects of KN056 in Healthy Participants

Type 2 Diabetes

New Zealand
Allegro Ophthalmics, LLC
Duke University; Trial Runners, LLC

Completed

A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy

Non-Proliferative Diabetic Retinopathy

United States
Hanscom, Thomas, M.D.
Genentech, Inc.

Completed

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab (RAVEN)

Central Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein Occlusion

United States
JW Pharmaceutical

Completed

Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

Hyperuricemia | Gout

Korea, Republic of
The Affiliated Hospital of Qingdao University

Completed

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Healthy Volunteers

China
Guangdong Raynovent Biotech Co., Ltd

Completed

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics

Nonalcoholic Steatohepatitis

China
Stealth BioTherapeutics Inc.

Completed

A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)

Healthy

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Completed

Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Diffuse Large B Cell Lymphoma，DLBCL

China
West China Hospital

Recruiting

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Esophageal Squamous Cell Carcinoma

China
West China Hospital

Recruiting

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas

Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of SYHA1402 in Healthy Subjects

Diabetic Peripheral Neuropathy
BeBetter Med Inc

Completed

Study of Orally Administered BEBT-503 in Healthy Subjects

Healthy Subjects

Australia
Peter A Campochiaro, MD
Genentech, Inc.

Completed

Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions (RELATE)

Retinal Vein Occlusion

United States
Eye Center of Northern Colorado, P.C.
Genentech, Inc.

Completed

High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia (HD-LIPT)

Retinal Diseases | Telangiectasis

United States
Retina Consultants of Hawaii
Genentech, Inc.

Unknown

Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy (PEARL2)

Polypoidal Choroidal Vasculopathy

United States
Aridis Pharmaceuticals, Inc.

Completed

Study of Single Doses of IV Aerucin in Healthy Adults

Healthy

United States
Allegro Ophthalmics, LLC
Duke University; Trial Runners, LLC

Completed

Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema

Diabetic Macular Edema

United States
NuSirt Biopharma

Completed

The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

Obesity

United States
Arshad Khanani
Genentech, Inc.

Completed

Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Linda Van Eldik
National Institute on Aging (NIA); Duke Clinical Research Institute

Completed

MW151-101: First-in-human Study of MW151

Drug Toxicity

United States
GlaxoSmithKline

Completed

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

Hepatitis C

United States
Sun Yat-sen University

Terminated

Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy

Polypoidal Choroidal Vasculopathy

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

A Randomized, Double-blind,Dose-escalating, Single-dose, Oral Phase I Clinical Study of Flunotinib Healthy People

Healthy Person

China
Genfit
Naturalpha; SGS Aster S.A.S.

Completed

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Cardiovascular Diseases | Metabolic Diseases | Diabetes Mellitus, Type 2 | Type 2 Diabetes | Dyslipidemia | Obese

France
Incepta Pharmaceuticals Ltd
Institute for Developing Science and Health Initiatives, Bangladesh

Recruiting

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Macular Degeneration | Retinal Degeneration | Diabetic Retinopathy | Diabetic Macular Edema | Macular Edema | Retinal Disease

Bangladesh
Jiangsu Nhwa Pharmaceutical Co., Ltd.

Recruiting

A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects

Schizophrenia

China
Dong-A ST Co., Ltd.

Active, not recruiting

Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults

Healthy

Korea, Republic of
Shire

Terminated

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Schizophrenia

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

Healthy Participants

China
Xention Ltd

Completed

Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103

Atrial Fibrillation

United Kingdom
Zambon SpA

Withdrawn

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

Parkinson Disease | Dyskinesia, Drug-Induced
Shaheer A. Khan
AstraZeneca; Melanoma Research Alliance

Completed

Intermittent Selumetinib for Uveal Melanoma

Uveal Melanoma

United States
GlaxoSmithKline

Withdrawn

GSK2190915 Pediatric Study

Asthma
Samsung Medical Center
Dong-A Pharmaceutical Co., Ltd.

Unknown

Zydena on Cognitive Function of Alzheimer's Disease Patients

Alzheimer's Disease

Korea, Republic of
Samjin Pharmaceutical Co., Ltd.

Completed

A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Healthy

Korea, Republic of
Inmagene LLC

Completed

Study to Evaluate IMG-004 in Healthy Participants

Healthy Participants

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)

Branch Retinal Vein Occlusion

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Advanced Liver Cancer

China
LG Life Sciences

Completed

Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients

Hypertension

Korea, Republic of
Henry M. Jackson Foundation for the Advancement...
Gilead Sciences

Withdrawn

Antiretroviral Therapy for Acute HIV Infection

HIV Infections

Uganda
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Central Retinal Vein Occlusion

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE)

Plaque-type Psoriasis

United States, Austria, Germany, France, Japan, Canada, Slovakia, India
University of Campania "Luigi Vanvitelli"

Completed

Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia

Myopia, Degenerative
University of Illinois at Chicago
Genentech, Inc.

Withdrawn

Lucentis for New Onset Neovascular Glaucoma (NVG)

Glaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
Especialistas en Retina Medica y Quirurgica Grupo...
Centro de Retina Medica y Quirurgica S.C.

Completed

MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2) (MINIMA-2)

Diabetic Macular Edema

Argentina, Mexico
Lupin Ltd.

Recruiting

Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD

Neovascular Age-related Macular Degeneration

India
Hawaii Pacific Health
Genentech, Inc.

Completed

Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) (PEARL2)

Polypoidal Choroidal Vasculopathy | PCV

United States
New England Retina Associates
Genentech, Inc.

Completed

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Choroidal Melanoma

United States

Search clinical trials for: ranibizumab 1.0mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations